Kinimmune

Kinimmune

Biotechnology, 4340 Duncan Ave, St Louis, Missouri, 63110, United States, 1-10 Employees

kinimmune.bio

  • LinkedIn

phone no Phone Number: +13*********

Who is KINIMMUNE

Kinimmune is a clinical-stage pharmaceutical company developing intratumoral immunostimulants for unlocking the full potential of checkpoint inhibition in solid tumors. Precision drug del...

Read More

map
  • 4340 Duncan Ave, St Louis, Missouri, 63110, United States Headquarters: 4340 Duncan Ave, St Louis, Missouri, 63110, United States
  • 2020 Date Founded: 2020
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 6799; 8742 | NAICS Code: 523910 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from KINIMMUNE

Kinimmune Org Chart and Mapping

Employees

Danny Griffin

Chief Scientific Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Kinimmune

Answer: Kinimmune's headquarters are located at 4340 Duncan Ave, St Louis, Missouri, 63110, United States

Answer: Kinimmune's phone number is +13*********

Answer: Kinimmune's official website is https://kinimmune.bio

Answer: Kinimmune's revenue is $10 Million to $25 Million

Answer: Kinimmune's SIC: 6799; 8742

Answer: Kinimmune's NAICS: 523910

Answer: Kinimmune has 1-10 employees

Answer: Kinimmune is in Biotechnology

Answer: Kinimmune contact info: Phone number: +13********* Website: https://kinimmune.bio

Answer: Kinimmune is a clinical-stage pharmaceutical company developing intratumoral immunostimulants for unlocking the full potential of checkpoint inhibition in solid tumors. Precision drug delivery for tuning the immune system. Kinimmune is discovering and developing quick-to-market intratumoral immunotherapies for maximized safety and efficacy in solid tumors. Our immunotherapy products address unmet medical needs by applying our technologies to parent drugs with clinical proof-of-concept or clinically validated pathways. This strategy stands to benefit cancer patients by enabling new therapeutic interventions with proven track records and minimalized safety burdens. With extensive team experience in biotechnology and immunotherapy, were working to harness the immune system's potential to fight cancer.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access